##  [Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up](/us-en/news/media-releases/novartis-kymriah-demonstrates-strong-responses-high-risk-patients-relapsed-or-refractory-follicular-lymphoma-extended-study-follow-0 "Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up") 

  Dec 11, 2021